Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Pelion SA (PELIO)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
Pelion SA historical data, for real-time data please try another search
58.80 0.00    0.00%
07/06 - Delayed Data. Currency in PLN ( Disclaimer )
Type:  Equity
Market:  Poland
ISIN:  PLMEDCS00015 
  • Volume: 0
  • Bid/Ask: 58.81 / 58.94
  • Day's Range: 58.80 - 58.98
Pelion SA 58.80 0.00 0.00%

Pelion SA Company Profile

 
Get an in-depth profile of Pelion SA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Providers & Services
SectorHealthcare
Employees

8973

Equity Type

ORD

Pelion S.A. engages in the trade of pharmaceuticals, cosmetics, and parapharmaceuticals in Poland. It operates through Wholesale, Retail, and Hospital supplies and logistics services segments. The company is involved in the wholesale and retail sale of pharmaceuticals to pharmacies, outpatient clinics, medical stores, etc., as well as in-patient healthcare institutions, hospitals, and wholesalers; and retail sale of dermocosmetics, such as personal care cosmetics, make-up products, nail care products, hair and body care products, and fragrances. It operates approximately 900 outlets under the DOZ Apteki dbam o zdrowie brand name; 300 beauty stores under the Natura name; 330 own and franchise pharmacies under the Gintarine Vaistine and Norfos Vaistine brands; 140 BVG partner pharmacies; e-pharmacies, including doz.pl and vaistine; and beauty e-stores comprising drogerienatura.pl and dozdrogeria.pl, as well as publishes Farmakoekonomika szpitalna, a quarterly magazine distributed to hospitals and pharmacies. The company also offers logistics services related to the management, warehousing, and distribution of drugs for the pharmaceutical industry; and business process outsourcing services, such as outsourcing of accounting and reporting, HR and payroll, management accounting, tax, financing process support, and business advisory services, as well as consolidation of financial statements. In addition, it provides credit risk management, contract-based manufacturing, and medical services, as well as pharmaceutical insurance products based on private drug refund schemes; develops and commercializes anti-atherogenic drugs, dermocosmetics, food and dietary supplements, and galenic preparations; and designs and develops healthcare solutions. Pelion S.A. was formerly known as Polska Grupa Farmaceutyczna SA and changed its name to Pelion S.A. in November 2011. The company was founded in 1990 and is based in Lódz, Poland.

Contact Information

Address ul. Zbaszynska 3
Lódz, 91-342
Poland
Phone 48 42 200 7805
Fax 48 42 200 7535
Web www.pelion.eu
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

PELIO Comments

Write your thoughts about Pelion SA
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email